ALNY
Closed
Alnylam Pharmaceuticals Inc
322.06
-4.03 (-1.24%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 326.09
Day's Range: 315.03 - 326.64
Send
sign up or login to leave a comment!
When Written:
200.32
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development of RNA interference (RNAi) therapeutics. RNAi is a natural biological process that regulates gene expression by silencing or "turning off" specific genes. Alnylam uses this technology to develop drugs that target genetic diseases.
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam has a pipeline of RNAi therapeutics in various stages of development for a range of diseases, including rare genetic disorders, cardiovascular diseases, and infectious diseases.
Alnylam's first commercial product, Onpattro (patisiran), was approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). This is a rare, progressive disease caused by the buildup of abnormal protein deposits in various tissues and organs.
Alnylam has partnerships with other pharmaceutical companies, including Sanofi, Regeneron, and Novartis, to develop and commercialize RNAi therapeutics. The company has received numerous awards and recognition for its innovative approach to drug development, including being named one of the world's most innovative companies by Forbes magazine.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam has a pipeline of RNAi therapeutics in various stages of development for a range of diseases, including rare genetic disorders, cardiovascular diseases, and infectious diseases.
Alnylam's first commercial product, Onpattro (patisiran), was approved by the US Food and Drug Administration (FDA) in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). This is a rare, progressive disease caused by the buildup of abnormal protein deposits in various tissues and organs.
Alnylam has partnerships with other pharmaceutical companies, including Sanofi, Regeneron, and Novartis, to develop and commercialize RNAi therapeutics. The company has received numerous awards and recognition for its innovative approach to drug development, including being named one of the world's most innovative companies by Forbes magazine.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








